Citadel Advisors
KAPA

Citadel Advisors’s Kairos Pharma KAPA Stock Holding History

Citadel Advisors’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
+44,262
New +$161K ﹤0.01% 12545
2026
Q1 		– Sell
-45,963
Closed -$228K – 14539
2025
Q4 		$228K Buy
+45,963
New +$301K ﹤0.01% 10748
2025
Q2 		– Sell
-1,890
Closed -$12.4K – 15613
2025
Q1 		$12.4K Buy
1,890
+323
+21% +$2.9K ﹤0.01% 13450
2024
Q4 		$16.7K Buy
+1,567
New +$16.8K ﹤0.01% 13291

Other funds holding KAPA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Citadel Advisors's KAPA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Kairos Pharma (KAPA) in Q2 2026: 44,262 shares worth $119K. The stake represents ﹤0.01% of the portfolio and ranks #12545 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in KAPA as recently as Q4 2025.

Citadel Advisors first reported a position in KAPA in Q4 2024 and has held it in 4 quarters since. The position peaked at $228K in Q4 2025. 14 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • Citadel Advisors held 44,262 shares of Kairos Pharma worth $119K as of Q2 2026.
  • Kairos Pharma was a new Citadel Advisors position in Q2 2026.
  • Kairos Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12545 holding.
  • Citadel Advisors first reported a position in Kairos Pharma in Q4 2024 and has held it in 4 quarters since.
  • Citadel Advisors's Kairos Pharma position peaked at $228K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.